Benzinga··Nabaparna BhattacharyaEsperion Soars 57% on $1.1B ARCHIMED Buyout Deal
Esperion Therapeutics agreed to be acquired by ARCHIMED for $1.1 billion, with shareholders receiving $3.16 per share plus up to $100 million in contingent payments—a 58% premium driving 57.5% premarket gains.
ESPRacquisitionshareholder value